GLP-1 drugs may reduce alcohol use: systematic review of three clinical trials | Research

The takeaway

A systematic review of three RCTs (n=48-151) found semaglutide and dulaglutide reduced alcohol use, while exenatide showed no significant effect on heavy drinking days.

2 of 3 drugs effective
Semaglutide and dulaglutide reduced alcohol use in controlled trials, supporting the hypothesis that GLP-1 drugs affect brain reward pathways

What the researchers found

Semaglutide reduced alcohol use; dulaglutide lowered intake in current drinkers; exenatide showed no significant effect on heavy drinking days. Three RCTs reviewed (n=48-151).

Why it matters

Alcohol use disorder has few effective pharmacotherapies. If GLP-1 drugs—already widely prescribed for diabetes and obesity—also reduce alcohol consumption, they could address a major unmet medical need and benefit patients with overlapping conditions.

The numbers in context

Three RCTs reviewed (n = 48-151). Semaglutide reduced alcohol use. Dulaglutide lowered intake in current drinkers. Exenatide had no significant effect on heavy drinking days.

How the study worked

Systematic review of three randomized controlled trials (n=48-151) examining GLP-1 receptor agonists for alcohol use outcomes.

Who was studied

Adults with alcohol use or alcohol use disorder

What this study cannot tell us

Only three small RCTs available. Sample sizes were small (48-151). Not all GLP-1 drugs showed effects. Alcohol outcomes were not always primary endpoints. Larger, dedicated trials needed.

How to read the evidence

Systematic review of RCTs (good methodology) but limited by only 3 small trials with varying designs. Promising but preliminary evidence.

When this study was published

Published in 2025; summarizes the first controlled trial data on GLP-1 drugs and alcohol use.

The bigger picture

GLP-1 receptors in the brain's reward centers may explain why these drugs reduce addictive behaviors. This systematic review adds controlled evidence to the growing observational data, potentially expanding GLP-1 drug indications into addiction medicine.

Questions still open

Why does semaglutide appear more effective than exenatide for alcohol reduction?
Are brain-penetrant GLP-1 drugs more effective for addiction applications?
Would larger trials with alcohol use disorder as primary endpoint confirm these findings?

Common questions

Can GLP-1 drugs help with alcohol addiction?

Early evidence suggests they might. This review found semaglutide and dulaglutide reduced alcohol use in small clinical trials. GLP-1 receptors exist in brain reward centers, which may explain why these drugs reduce the desire to drink. However, much larger studies are needed before these drugs can be recommended for alcohol use disorder.

Why might weight loss drugs reduce alcohol consumption?

GLP-1 drugs work partly by acting on brain reward pathways that control appetite and pleasure. These same pathways are involved in alcohol craving. By modifying reward signaling, GLP-1 drugs may reduce the pleasurable effects of alcohol and decrease the urge to drink.

Read the original research

GLP-1 receptor agonists and alcohol use disorder: a systematic review.

Alcohol and alcoholism (Oxford, Oxfordshire), 61(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Patel, Sheel; Blaney, Hanna; Nassar, Sarah; Singal, Ashwani K. (2025). GLP-1 receptor agonists and alcohol use disorder: a systematic review.. Alcohol and alcoholism (Oxford, Oxfordshire), 61(1). https://doi.org/10.1093/alcalc/agaf069